Back to Search
Start Over
Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
- Source :
- BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019), BMC Cancer
- Publication Year :
- 2019
- Publisher :
- BMC, 2019.
-
Abstract
- Background Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. Objective Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. Methods Tissue biopsies from 6 patients with suspected CNSL were analyzed using a 649gene next-generation sequencing (NGS) tumor panel (tumor vs. reference tissue (EDTA-blood)). The individual somatic mutation pattern was used as a basis for the digital PCR analyzing circulating tumor DNA (ctDNA) from plasma and cerebrospinal fluid (CSF) samples, identifying one selected tumor mutation during this first step of the feasibility investigation. Results NGS-analysis of biopsy tissue revealed a specific somatic mutation pattern in all confirmed lymphoma samples (n = 5, NGS-sensitivity 100%) and none in the sample identified as normal brain tissue (NGS-specificity 100%). cfDNA-extraction was dependent on the extraction-kit used and feasible in 3 samples, in all of which somatic mutations were detectable (100%). Analysis of CSF-derived cfDNA was superior to plasma-derived cfDNA and routine microscopic analysis (lymphoma cells: n = 2, 40%). One patient showed a divergent molecular pattern, typical of Burkitt-Lymphoma (HIV+, serologic evidence of EBV-infection). Lumbar puncture was tolerated without complications, whereas biopsy caused 3 hemorrhages. Conclusions Our investigation provides evidence that analysis of cfDNA in central nervous system tumors is feasible using the described protocol. Molecular characterization of CNSL could be achieved by analysis of CSF-derived cfDNA. Knowledge of a tumor’s specific mutation pattern may allow initiation of targeted therapies, treatment surveillance and could lead to minimally-invasive diagnostics in the future. Electronic supplementary material The online version of this article (10.1186/s12885-019-5394-x) contains supplementary material, which is available to authorized users.
- Subjects :
- Adult
Male
0301 basic medicine
Cancer Research
Pathology
medicine.medical_specialty
Lymphoma, B-Cell
Case Report
Sensitivity and Specificity
lcsh:RC254-282
Circulating Tumor DNA
Stereotaxic Techniques
03 medical and health sciences
0302 clinical medicine
Germline mutation
Cerebrospinal fluid
Targeted therapies
Surgical oncology
Biopsy
Genetics
medicine
Humans
Digital polymerase chain reaction
Circulating DNA
Liquid biopsy
Aged
medicine.diagnostic_test
Brain Neoplasms
Lumbar puncture
business.industry
High-Throughput Nucleotide Sequencing
Sequence Analysis, DNA
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Magnetic Resonance Imaging
Personalized medicine
Lymphoma
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Mutation
Female
CNS-lymphoma
Tomography, X-Ray Computed
business
Cell-Free Nucleic Acids
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 19
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC Cancer
- Accession number :
- edsair.doi.dedup.....6ce00ee546a864de6b0d3f6397c8aa31